Healthcare Professionals   /   OncoLink Scientific Meetings Coverage   /   ASTRO   /   OncoLink at ASTRO 1999   /   OncoLink at ASTRO 1999: Monday November 1

Radiation Therapy With Concurrent Weekly Carboplatin and Paclitaxol in Advanced Stage Unresectable Squamous Cell Carcinoma of the Head and Neck

James Metz, MD
OncoLink Associate Editor
Last Modified: November 1, 1999

Presenter: Michael L. Haas, MD
Affiliation: University of Maryland

Summary:
Advanced squamous cell carcinoma of the head and neck region generally has a poor outcome with radiation therapy alone. This study was designed to evaluate concurrent chemoradiation therapy for the treatment of unresectable head and neck cancer.

Methods:
From 1993-1998 62 patients received weekly carboplatin/taxol chemotherapy with radiation therapy. Radiation was delivered to a total dose of 70.2 Gy in 1.8 Gy fractions to the primary site. The majority of patients had oropharyngeal cancer.

Results:

• The complete response rate was 82% at the primary site and 63% in the neck nodes.
• Overall, 75% had no clinical evidence of residual disease at the completion of therapy.
• With a median follow-up of 30 months, the overall survival at 3 years was 48%.
• The local control rate at 3 years was 63%.

ASTRO coverage is sponsored, in part, by Varian Medical Systems, Inc.